

Boltz
Also known as Boltz PBC, Boltz, PBC
A public benefit corporation started by MIT researchers who released the open Boltz-1, Boltz-2 and BoltzGen models for biomolecular structure, binding affinity and binder design. It keeps those open and sells its newer proprietary models, BoltzMol-1 and BoltzProt-1, to drugmakers and industrial companies through the Boltz Lab interface and an API, fine-tuning them on a partner's own data.
Money and evidence
Latest round, Series A, 2026-11-18: the record then held 1 research entry, highest level 4. The first research entry is dated 2026-09-15; the highest level so far is 4 (Tested in the physical world).
Rounds and research, on one timeline
- 2026-11-18Series ARound
$110M
For: compute and data, meeting demand from its pharma and industrial partners, and a larger team
Models and platformData generationHiring
The company's post names Bessemer's Andrew Hedin and Byron Deeter as coming in with the round, says all existing investors took part again, and adds that other new investors are not listed. It states no valuation. Boltz says six of the world's 20 largest pharmaceutical companies use the platform and that molecular tokens processed for paying customers have grown 50-fold since June.
Lead · Bessemer Venture Partners
Greycroft
F-Prime
Hummingbird Ventures
Benchling
Existing investor · a16z
Existing investor · Amplify PartnersExisting investor · Zetta Venture Partners
Existing investor · Obvious VenturesOn the deal: Andrew Hedin (Partner; the announcement names them as coming in with the round, Bessemer Venture Partners); Byron Deeter (Partner; the announcement names them as coming in with the round, Bessemer Venture Partners)
By this date the record held 1 research entry, highest level 4
- 2026-09-15Research
Level 4 · Tested in the physical world
Boltz picked 27 compounds for Werner helicase with BoltzMol-1, and three of them inhibited the enzyme in the
micromolar range Novartis reached its clinical WRN inhibitor HRO761 through three screening campaigns of nearly 350,000 compounds that left one usable hit, and the chemistry around it is now crowded: Boltz counts 62 patent publications from 36 organisations sharing the candidate's core. Its own two hits are chemically unlike it, at 0.08 and 0.14 on a 0-to-1 similarity scale, while the nearest compound in the model's affinity training data sits at 0.365. That is what a buyer of these tools wants: a different starting point for one chemist, two days of computing and a week of assays.
- 2026-01-08SeedRound
$28M
For: the team, the Boltz Lab platform and its small-molecule and protein design agents
Models and platformHiring
The company's launch post of 8 January names the backers without calling any of them a lead, and lists Hugging Face CEO Clement Delangue among strategic angels. It was announced the same day as the Pfizer collaboration and the Boltz Lab beta.
Zetta Venture Partners
Amplify Partners
a16zFactorial Capital
Obvious VenturesClement Delangue
Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.
Its investors also backed
Other companies on this page whose rounds name the same investor.
- a16zBigHat Biosciences, Inceptive, Genesis Molecular AI (formerly
Genesis Therapeutics) , Periodic Labs, Isomorphic Labs, Mirendil - Obvious VenturesInceptive, LabGenius, Radical Numerics, Mithrl
- F-PrimeXaira Therapeutics, Albert, Owkin, Insilico Medicine
- Hummingbird VenturesEnveda, Noetik, Basecamp Research, Bioptimus
- GreycroftAMI Labs, Recursive Superintelligence
- Amplify PartnersAxiom Bio, Achira
- Bessemer Venture PartnersConverge Bio
- Zetta Venture PartnersNoetik